Selecting the Right 3PL

The acquisition of Cryoport’s specialty courier business is now finalized, with a value of approximately $200 million.

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one.

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

As this medical approach continues to become more widely adopted, the industry must adapt to help provide precise, compliant, temperature-controlled, delivery of highly individualized treatments.

Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by real-time data.